Brent Saunders, Bausch + Lomb CEO (Richard Drew/AP Images)
All eyes on Brent Saunders: Bausch + Lomb dealmaker to buy Xiidra from Novartis in $1.75B deal
Brent Saunders is making deals yet again.
In his return to the helm of Bausch + Lomb, Saunders will broaden the eye-care company’s portfolio with a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
